BINTRAFUSP ALFA
UNII NW9K8C1JN3

Substance Identification & Data

This profile provides standardized clinical and technical data for Bintrafusp Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) NW9K8C1JN3.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1918149-01-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

NW9K8C1JN3

CAS Registry Number

1918149-01-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BINTRAFUSP ALFA

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C124229

National Cancer Institute reference terminology for clinical and research data.

INN ID

10665

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

HI-200

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Bintrafusp Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

BINTRAFUSP ALFA

Common Names & Synonyms

ANTI-PD-L1/TGFBETARII FUSION PROTEIN MSB0011359C

BINTRAFUSP ALFA [INN]

BINTRAFUSP ALFA [JAN]

BINTRAFUSP ALFA [USAN]

BINTRAFUSP ALFA [WHO-DD]

IMMUNOGLOBULIN G1, ANTI-(HUMAN PROGRAMMED CELL DEATH 1 LIGAND PROTEIN)(HUMAN .GAMMA.1-CHAIN) FUSION PROTEIN WITH 2-137-TRANSFORMING GROWTH FACTOR .BETA. RECEPTOR (HUMAN GENE TGFBR2 ISOFORM 1), DISULFIDE WITH ANTI-(HUMAN PROGRAMMED CELL DEATH 1 LIGAND PROTEIN)(HUMAN .LAMBDA.-CHAIN), DIMER

IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP